Results 71 to 80 of about 41,247 (202)
Clinical &Translational Immunology, Volume 15, Issue 3, 2026.Immunisation with adenovirus (Ad) vectors followed by Modified Vaccinia Virus Ankara—strain Bavarian Nordic (MVA‐BN) vectors expressing HPV16 and HPV18 engineered antigens induced antigen‐specific polyfunctional T cells in mice, rhesus macaques and persistent HPV16/HPV18 infected human females vaccines (n = 5). These data showed the promise of the Ad26‐
Selina Khan +15 more
wiley +1 more source
Frontiers in ImmunologyVaccines have historically played a pivotal role in controlling epidemics. Effective vaccines for viruses causing significant human disease, e.g., Ebola, Lassa fever, or Crimean Congo hemorrhagic fever virus, would be invaluable to public health ...
Duane C. Harris +13 more
doaj +1 more source
Ebola virus disease: Recent advances in diagnostics and therapeutics
Asian Pacific Journal of Tropical Medicine, 2019 Ebola virus disease (EVD) is associated with haemorrhagic fever in humans and nonhuman primates, with a high rate of fatality (up to 90%). Some outbreaks in human history have proven the lethality of EVD.
Supriya Jagga +3 more
doaj +1 more source
Recent updates on correlates of vaccine-induced protection
Frontiers in Immunology, 2023 Correlates of protection are key for vaccine development against any pathogen. In this paper we summarize recent information about correlates for vaccines against dengue, Ebola, influenza, pneumococcal, respiratory syncytial virus, rotavirus, shigella ...
Stanley A. Plotkin, Stanley A. Plotkin
doaj +1 more source
Uirusu, 2015 Filoviruses (Ebola and Marburg viruses) cause severe hemorrhagic fever in humans and nonhuman primates. No effective prophylaxis or treatment for filovirus diseases is yet commercially available. The recent outbreak of Ebola virus disease in West Africa has accelerated efforts to develop anti-Ebola virus prophylaxis and treatment, and unapproved drugs ...
openaire +3 more sources
Cell, 2020 Ervebo is the first licensed vaccine for prevention of Ebola virus disease. The vaccine, originally developed by the Public Health Agency of Canada, is delivered in a single 1 mL dose and has been delivered to >200,000 people in an ongoing 2018-2020 outbreak of disease. To view this Bench to Bedside, open or download the PDF.
openaire +2 more sources
A review of epidemiological parameters from Ebola outbreaks to inform early public health decision-making. [PDF]
, 2015 The unprecedented scale of the Ebola outbreak in West Africa has, as of 29 April 2015, resulted in more than 10,884 deaths among 26,277 cases. Prior to the ongoing outbreak, Ebola virus disease (EVD) caused relatively small outbreaks (maximum outbreak ...
Bento, AI +4 more
core +1 more source
Fractional Order Epidemic System of Saturated Rate of Incidence: A Neural Network Approach
Engineering Reports, Volume 8, Issue 3, March 2026.The workflow depictions of the mathematical fractional order saturated rate of incidence model using the process of Levenberg–Marquardt Backpropagation neural network. The designed neural network contains 20 numbers of neurons, a sigmoid activation function, and a single hidden layer structure.
Zulqurnain Sabir +3 more
wiley +1 more source
F1000Research, 2015 The ongoing Ebola virus epidemic has presented numerous challenges with respect to control and treatment because there are no approved drugs or vaccines for the Ebola virus disease (EVD).
Veljko Veljkovic +7 more
doaj +1 more source
Global Health Security in an Era of Explosive Pandemic Potential [PDF]
, 2017 Pandemics pose a significant risk to security, economic stability, and development. Annualized expected losses from pandemics are estimated at $60 billion per year. Despite the certainty and magnitude of the threat, the global community has significantly
Ayala, Ana, Gostin, Lawrence O.
core +1 more source